CLINICAL_TRIALS trial_result · 2023-03-21

Clinical Trial Update: Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy [Phase 1]

Phase 1 trial assessing safety and tolerability of sc immunotherapy DM-101 in adults with birch pollen allergy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Desentum Oy | Conditions: Birch Pollen Allergy | Phase 1 | Status: COMPLETED | Results posted: 2023-03-21